medigraphic.com
ISSN 1561-3070 (Electronic)

2021, Number 3

<< Back Next >>

Rev Cub Oftal 2021; 34 (3)

Different concentrations of mitomycin C for haze prevention in photorefractive keratectomy

Pérez GD, García GF, Novoa SE, Ventura FCA, Arroyo TM

Language: Spanish
References: 19
Page: 1-17
PDF size: 474.66 Kb.


ABSTRACT

Objective: Evaluate the usefulness of two concentrations of mitomycin C for haze prevention in photorefractive keratectomy.
Methods: An experimental randomized study was conducted of 26 eyes of 17 patients with myopic defects. The patients were divided into two groups according to their mitomycin C doses (Group 1: 0.02% and Group 2: 0.002%). The main response variable was the presence of haze. Verification was performed of the correlation between haze magnitude and the degree of the ametropia treated, ablation depth, endothelial microscopy, and visual and refractive results.
Results: At six months most patients in Group 1 did not have any haze (eight eyes / 57%), whereas 0.5 (6 eyes / 50%) in Group 2 still had haze. In severe ametropia, haze was larger in Group 2 than in Group 1 throughout the postoperative period, the greatest difference being observed in the sixth month with 0.5 ± 0.4 vs 1.5 ± 0.32. In ablations > 75 microns, Group 2 ended with more haze than Group 1, with 0.5 ± 0.44 vs 1.75 ± 0.76. Uncorrected visual acuity was more affected in Group 2. No endothelial damage occurred in either group.
Conclusion: The presence of haze prevails in cases treated with 0.002% doses of mitomycin C, as compared with 0.02% doses, though in this case both groups maintained an appropriate visual and refractive result and low endothelial toxicity.


REFERENCES

  1. Daizong Wen. Postoperative efficacy, predictability, safety and visual quality of laser corneal refractive surgery: a network meta-analysis. Soy J Ophthalmol. 2017;178:65-78. DOI: http://doi.org/10.1016/j.ajo.2017.03.013

  2. Li SM. Laser assisted subepitelial keratectomy (Lasek) versus photorefractive keratectomy (PRK) for correction of myopia. Cochrane database Syst Rev. 2016;2. DOI: http://doi.org/10.1002/14651858.CD009799.pub2

  3. Zhu X. Comparation of postoperative visual quality after SMILE and LASEK for high myopia: 1 year outcome. PLoS One. 2017;12(8). DOI: http://doi.org/10.1371/journal.pone.0182251

  4. Arranz-Marquez E, Katsanos Andreas, Kozobolis V, Konstas A,Teus M. A critical overview of biological effects of Mitomicina C application on cornea folowing refractive surgery. Adv Ther. 2019;36:786-97. DOI: http:/doi-org/10.1007/s12325-019-00905-w

  5. Majmudar PA, Schallhorn SC, Cason JB, et.al. Mitomycin-C in corneal surface excimer laser ablation techniques: a report by the American Academy of Ophthalmology. Ophthalmology. 2015;122(6):1085-95. DOI: http://doi.org/10.1016/j.ophtha.2015.01.019

  6. Reilly CD, Paday V, Lazos V, Mittelstaedt BR. PRK vs. LASEK vs. Epi-LASIK: a comparison of corneal haze, postoperative pain and visual recovery in moderate to high myopia . Nepal J Ophthalmol. 2010;2(2):97-104. DOI: http://doi.org/10.3126/nepjoph.v2i2.3715

  7. Fazel F, Roshani L, Rezaei L. Two-step versus Single Application of Mitomycin-C in Photorefractive Keratectomy for High Myopia. J Ophthalmic Vis Res. 2012 [acceso: 12/08/2021];7(1):17-23. Disponible en: https://pubmed.ncbi.nlm.nih.gov/22737382/

  8. Pérez RG, Gómez EJ, Silva A, Pérez G, Cárdenas T, Guerra M. Lasek - Mitomicina C versus PRK- Mitomicina C en pacientes con miopía y astigmatismo miópico compuesto. Rev Cubana Oftalmol. 2019 [acceso: 12/08/2021];32(2). Disponible en: https://www.medigraphic.com/cgi-bin/new/resumen.cgi?IDARTICULO=94756

  9. Tirado MO, Hernández A. Uso de la Mitomicina C en la prevención del haze corneal. Rev Cub Oftal. 2011 [acceso: 12/08/2021];24(1). Disponible en: http://scielo.sld.cu/scielo.php?pid=S0864-21762011000100010&script

  10. Thornton I, Xu M, Krueger RR. Comparison of standard (0.02%) and low dose (0.002%) mitomycin C in the prevention of corneal haze following surface ablation for myopia. J Refract Surg 2008;24(1):S68-76. DOI: http://doi.org/10.3928/1081597X-20080101-13

  11. Coelho LM, Sieiro RO. Mitomycim C 0.02 and 0.002% efficacy in preventing haze after photorefractive keratectomy. Int. Ophthalmol. 2019;39(2):341-5. DOI: http://doi.org/10.1007/s10792-017-0817-7

  12. Zhao LQ, Wei RL, Cheng JW, Li Y, Cai JP, Ma XY. Meta-analysis: Clinical Outcomes of Laser-Assisted Subepithelial Keratectomy and Photorefractive Keratectomy in Myopia. Ophthalmology. 2010;117(10):1912-22. DOI: http://doi.org/10.1016/j.ophtha.2010.02.004

  13. Baz O. Photorefractive keratectomy in the correction of astigmatism using Schwind Amaris 750s laser. Ophthalmol. 2013;6(3):356-61. DOI: http://doi.org/10.3980/j.issn.2222-3959.2013.03.19

  14. Medeiros CS, MarinoGK, Kassance L, Thangavadiel S, Santhiago MR, Wilson SE, The impact of photorefractive keratectomy and Mitomycim C 0.02% on corneal nerves and their regeneration. J Refract Surg. 2019;3(2):132. DOI: http://doi.org/10.3928/1081597X-20181112-01

  15. Kim TI, Lee SY, Tchah H. Mitomycin C induced reduction of keratocytes and fibroblasts after photorefractive keratectomy. Invest Ophathalmol Vis Sci. 2004;45(9): 2978-84. DOI: http://doi.org/10.1167/iovs.04-0070

  16. Gharaee H, Zarei-Ghanvati S, Alizadeh R, Abrishami M. Endothelial cell changes after photorefractive keratectomy with graded usage of Mitomicin C. Int Ophathalmol. 2018;38(3):1211-7. DOI: http://doi.org/10.1007/s10792-017-0584-5

  17. Adib-Moghaddam S, Soleyman-Jahi S, Ttefagh G, Tofighi S, Grentzelos MA, Kymionis GD. Comparasion of single step transephilelial photorefractive keratectomy with and without Mitomicin C in mild to moderate myopia. J Refract Surg. 2018;34 (6):400-07. DOI: http://doi.org/10.3928/1081597X-20180402-02

  18. Ang BCH, Yap SC, Toh ZH, Lim EWL, Tan MMH, Nah GKM, Zhao PSB, Tan MCL. Refractive outcomes, corneal haze and endothelial cell loss after myopic photorefractive keratectomy in an Asian population: The Singapore Armed Forces'experience. Clin Exp Ophthalmol. 2020;48(5):558-68. DOI: http://doi.org/10.3928/1081597X-20180402-02

  19. Cabrera Martínez A, Cabrera Martínez JA. LASEK con Mitomicina C en altos defectos refractivos miópicos. Rev Cubana Oftalmol. 2009 [acceso: 12/08/2021];22(2). Disponible en: http://scielo.sld.cu/scielo.php?pid=S0864-21762009000200001&script=sci_arttext&tlng=pt




2020     |     www.medigraphic.com